Drug and Gene Delivery Devices Market Size, Share, Trends, Growth Outlook

Drug and Gene Delivery Devices Market is estimated to increase at a growth rate of 7.9% CAGR over the forecast period from 2024 to 2030.

The Drug and Gene Delivery Devices Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Route of Administration (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical), By Gene Delivery Vector (Viral, Non-viral), By Method (In situ, Ex vivo).

An Introduction to Drug and Gene Delivery Devices Market in 2024

The Drug and Gene Delivery Devices market in 2024 addresses the demand for innovative medical devices designed to deliver therapeutic agents, including drugs and genetic materials, to targeted sites within the body for the treatment of various diseases and disorders. These delivery devices encompass a wide range of technologies, such as drug-eluting stents, implantable pumps, inhalers, and viral vectors for gene therapy, enabling precise and controlled administration of therapeutic payloads to specific tissues or cells. Market dynamics are driven by factors such as the increasing prevalence of chronic diseases requiring targeted therapies, advancements in drug formulation and delivery technologies, and the growing interest in personalized medicine and gene-based therapies. Collaboration between medical device manufacturers, pharmaceutical companies, and research institutions drives innovation and market growth in drug and gene delivery devices, facilitating the development of novel treatment modalities and improving patient outcomes in diverse therapeutic areas.

Drug and Gene Delivery Devices Market Trend: Advancements in Nanotechnology and Biotechnology

A prominent trend in the Drug and Gene Delivery Devices market is the rapid advancements in nanotechnology and biotechnology. These technological innovations have revolutionized the field of drug and gene delivery by offering more efficient and targeted delivery systems. Nanotechnology enables the design of nanoparticles and nanocarriers capable of encapsulating drugs or genetic material, allowing for controlled release and improved therapeutic efficacy. Additionally, advancements in biotechnology have led to the development of gene delivery vectors, such as viral vectors and lipid nanoparticles, that enable precise delivery of genetic material to target cells for gene therapy applications. These advancements drive the development of novel drug and gene delivery devices, catering to the growing demand for personalized and precision medicine.

Drug and Gene Delivery Devices Market Driver: Increasing Incidence of Chronic Diseases and Genetic Disorders

A key driver in the Drug and Gene Delivery Devices market is the increasing incidence of chronic diseases and genetic disorders worldwide. Chronic diseases such as cancer, diabetes, cardiovascular diseases, and neurological disorders impose a significant health burden globally, driving the demand for innovative drug delivery devices that enhance therapeutic outcomes and patient adherence. Moreover, the rising prevalence of genetic disorders and rare diseases necessitates the development of gene delivery devices capable of delivering therapeutic genes to correct genetic mutations and restore normal cellular function. As the incidence of these conditions continues to rise, there is a growing need for drug and gene delivery devices that offer targeted, efficient, and safe delivery of therapeutic agents, fueling market growth in the Drug and Gene Delivery Devices segment.

Drug and Gene Delivery Devices Market Opportunity: Integration of Smart Technologies and Biomaterials

One potential opportunity in the Drug and Gene Delivery Devices market lies in the integration of smart technologies and biomaterials to enhance device functionality and performance. Smart drug delivery devices equipped with sensors, actuators, and feedback mechanisms can enable real-time monitoring of drug release kinetics, patient compliance, and therapeutic response, allowing for personalized and adaptive therapy regimens. Furthermore, the use of biomaterials with tunable properties such as biocompatibility, biodegradability, and immunogenicity offers opportunities to design drug and gene delivery devices that mimic the physiological environment and promote targeted delivery to specific tissues or cells. By investing in the development of smart drug delivery devices and biomaterial-based delivery platforms, companies can address unmet clinical needs, improve patient outcomes, and differentiate their products in the competitive Drug and Gene Delivery Devices market.

Drug and Gene Delivery Devices Market Segmentation

By Route of Administration
Oral
Inhalation
Transdermal
Injectable
Ocular
Nasal
Topical
By Gene Delivery Vector
Viral
Non-viral
By Method
In situ
Ex vivo
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Drug and Gene Delivery Devices Market Companies

Amgen Inc
Bausch & Lomb Inc
Becton Dickinson and Company
Bluebird bio Inc
Castle Creek Biosciences Inc
Dendreon Pharmaceuticals
Helixmith Co. Ltd
Human Stem Cell Institute
Kite Pharma Inc
Kolon Tissue Gene Inc
Novartis AG
Orchard Therapeutics plc
Pfizer Inc
Renova Therapeutics
Spark Therapeutics Inc
uniQure N.V.
Vericel Corp
ViroMed Co. Ltd

 

 

Reasons to Buy the Drug and Gene Delivery Devices Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Drug and Gene Delivery Devices Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Drug and Gene Delivery Devices Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Drug and Gene Delivery Devices Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Drug and Gene Delivery Devices Market Size Outlook, $ Million, 2021 to 2030
3.2 Drug and Gene Delivery Devices Market Outlook by Type, $ Million, 2021 to 2030
3.3 Drug and Gene Delivery Devices Market Outlook by Product, $ Million, 2021 to 2030
3.4 Drug and Gene Delivery Devices Market Outlook by Application, $ Million, 2021 to 2030
3.5 Drug and Gene Delivery Devices Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Drug and Gene Delivery Devices Market Industry
4.2 Key Market Trends in Drug and Gene Delivery Devices Market Industry
4.3 Potential Opportunities in Drug and Gene Delivery Devices Market Industry
4.4 Key Challenges in Drug and Gene Delivery Devices Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Drug and Gene Delivery Devices Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Drug and Gene Delivery Devices Market Outlook By Segments
7.1 Drug and Gene Delivery Devices Market Outlook by Segments
By Route of Administration
Oral
Inhalation
Transdermal
Injectable
Ocular
Nasal
Topical
By Gene Delivery Vector
Viral
Non-viral
By Method
In situ
Ex vivo

8 North America Drug and Gene Delivery Devices Market Analysis And Outlook To 2030
8.1 Introduction to North America Drug and Gene Delivery Devices Markets in 2024
8.2 North America Drug and Gene Delivery Devices Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Drug and Gene Delivery Devices Market size Outlook by Segments, 2021-2030
By Route of Administration
Oral
Inhalation
Transdermal
Injectable
Ocular
Nasal
Topical
By Gene Delivery Vector
Viral
Non-viral
By Method
In situ
Ex vivo

9 Europe Drug and Gene Delivery Devices Market Analysis And Outlook To 2030
9.1 Introduction to Europe Drug and Gene Delivery Devices Markets in 2024
9.2 Europe Drug and Gene Delivery Devices Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Drug and Gene Delivery Devices Market Size Outlook By Segments, 2021-2030
By Route of Administration
Oral
Inhalation
Transdermal
Injectable
Ocular
Nasal
Topical
By Gene Delivery Vector
Viral
Non-viral
By Method
In situ
Ex vivo

10 Asia Pacific Drug and Gene Delivery Devices Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Drug and Gene Delivery Devices Markets in 2024
10.2 Asia Pacific Drug and Gene Delivery Devices Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Drug and Gene Delivery Devices Market size Outlook by Segments, 2021-2030
By Route of Administration
Oral
Inhalation
Transdermal
Injectable
Ocular
Nasal
Topical
By Gene Delivery Vector
Viral
Non-viral
By Method
In situ
Ex vivo

11 South America Drug and Gene Delivery Devices Market Analysis And Outlook To 2030
11.1 Introduction to South America Drug and Gene Delivery Devices Markets in 2024
11.2 South America Drug and Gene Delivery Devices Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Drug and Gene Delivery Devices Market size Outlook by Segments, 2021-2030
By Route of Administration
Oral
Inhalation
Transdermal
Injectable
Ocular
Nasal
Topical
By Gene Delivery Vector
Viral
Non-viral
By Method
In situ
Ex vivo

12 Middle East And Africa Drug and Gene Delivery Devices Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Drug and Gene Delivery Devices Markets in 2024
12.2 Middle East and Africa Drug and Gene Delivery Devices Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Drug and Gene Delivery Devices Market size Outlook by Segments, 2021-2030
By Route of Administration
Oral
Inhalation
Transdermal
Injectable
Ocular
Nasal
Topical
By Gene Delivery Vector
Viral
Non-viral
By Method
In situ
Ex vivo

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Amgen Inc
Bausch & Lomb Inc
Becton Dickinson and Company
Bluebird bio Inc
Castle Creek Biosciences Inc
Dendreon Pharmaceuticals
Helixmith Co. Ltd
Human Stem Cell Institute
Kite Pharma Inc
Kolon Tissue Gene Inc
Novartis AG
Orchard Therapeutics plc
Pfizer Inc
Renova Therapeutics
Spark Therapeutics Inc
uniQure N.V.
Vericel Corp
ViroMed Co. Ltd

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Route of Administration
Oral
Inhalation
Transdermal
Injectable
Ocular
Nasal
Topical
By Gene Delivery Vector
Viral
Non-viral
By Method
In situ
Ex vivo